Fig. 2: Tryptamine and phenethylamine are positively correlated with glucose intolerance in patients with type 2 diabetes and monkeys with spontaneous diabetes. | Nature Communications

Fig. 2: Tryptamine and phenethylamine are positively correlated with glucose intolerance in patients with type 2 diabetes and monkeys with spontaneous diabetes.

From: Gut microbiota-derived tryptamine and phenethylamine impair insulin sensitivity in metabolic syndrome and irritable bowel syndrome

Fig. 2

A, B Tryptamine and phenethylamine levels in fecal samples of individuals with or without T2D (n = 25 subjects with NGT, n = 25 patients with T2D). C, D Spearman’s correlation between fecal tryptamine/phenethylamine levels with FBG level in individuals with or without T2D (n = 25 subjects with NGT, n = 25 patients with T2D). E, F Tryptamine and phenethylamine levels in serum and fecal samples of age-matched monkeys with or without pre-diabetes and diabetes (n = 26/group). G, H Spearman’s correlation between fecal tryptamine/phenethylamine levels with HbA1c index in monkeys with or without pre-diabetes and diabetes (n = 26/group). I, J Spearman’s correlation between fecal tryptamine/phenethylamine levels with FBG index in monkeys with or without pre-diabetes and diabetes (n = 26/group). K, L Tryptamine and phenethylamine production in batch culture experiments using feces from monkeys with or without pre-diabetes and diabetes (n = 26/group). P values were determined by one-tailed ordinary two-way ANOVA or Student’s t-test. Data are presented as mean ± S.D. See additional information in Figure. S2.

Back to article page